🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523823-23-00
Completed Phase I

A study to test single and multiple doses of MER511 given to adults with Graves’ disease

2025-523823-23-00 · tracked via the Priya Life Science EU tracker
Sponsor
Merida Biosciences Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
22/05/2026
Enrollment target
28
Sites
Spain

Condition studied

Graves’ disease

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523823-23-00 on CTIS ↗ ← All trials in the EU